Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_2
1
50%
Ph phase_3
1
50%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
Phase 3Large-scale testing
1(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Terminated(1)
Other(1)

Detailed Status

Withdrawn1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 21 (50.0%)
Phase 31 (50.0%)

Trials by Status

withdrawn150%
unknown150%

Recent Activity

0 active trials
Showing 2 of 2
withdrawnphase_2

Safety and Efficacy of ALZT-OP1a as Adjuvant Treatment in Subjects With Post-Ischemic Stroke Cognitive Impairment (PSCI)

NCT03202147
unknownphase_3

Treatment of Acute Stroke With Cromolyn(Single Dose)

NCT01175525

Clinical Trials (2)

Showing 2 of 2 trials
NCT03202147Phase 2

Safety and Efficacy of ALZT-OP1a as Adjuvant Treatment in Subjects With Post-Ischemic Stroke Cognitive Impairment (PSCI)

Withdrawn
NCT01175525Phase 3

Treatment of Acute Stroke With Cromolyn(Single Dose)

Unknown

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2